Semaglutide research and evidence overview

Semaglutide research is not a collection of promising signals — it is one of the largest evidence bases ever assembled for a peptide drug. Completed randomized programs cover type 2 diabetes (SUSTAIN, PIONEER), obesity (STEP), cardiovascular events in 17,604 people (SELECT), kidney disease (FLOW), and liver disease (NASH phase 2), with the cagrilintide–semaglutide combination now through phase 3. The sections below walk the named trials with their sample sizes and results.

STEP (Semaglutide Treatment Effect in People with obesity) is the phase 3 program behind Wegovy. Its three most informative results:

• STEP 1 (n=1,961, 68 weeks): 2.4 mg weekly plus lifestyle intervention produced −14.9% mean body weight vs −2.4% with placebo (NEJM 2021).
• STEP 4 (n=803 randomized after a 20-week run-in): continuing semaglutide meant a further −7.9%; switching to placebo meant +6.9% regain — a 14.8-point difference that demonstrates the effect requires ongoing treatment (JAMA 2021).
• STEP 1 extension: one year after stopping drug and support, participants had regained about two-thirds of their lost weight, ending 5.6% below baseline versus 17.3% at treatment end (Diabetes, Obesity and Metabolism 2022).

Three event-driven trials moved semaglutide beyond surrogate markers:

• SUSTAIN-6 (n=3,297, type 2 diabetes at high cardiovascular risk): major adverse cardiovascular events occurred in 6.6% on semaglutide vs 8.9% on placebo (hazard ratio 0.74). The same trial produced the retinopathy safety signal (hazard ratio 1.76) that still appears in labels (NEJM 2016).
• SELECT (n=17,604, established cardiovascular disease and BMI ≥27, without diabetes): 2.4 mg weekly reduced major cardiovascular events by 20% — hazard ratio 0.80, event rates 6.5% vs 8.0% (NEJM 2023). SELECT is why Wegovy now carries a cardiovascular risk-reduction indication.
• FLOW (n=3,533, type 2 diabetes with chronic kidney disease): 24% lower risk of major kidney disease events — kidney failure, ≥50% eGFR loss, or kidney/cardiovascular death (hazard ratio 0.76; NEJM 2024).

The PIONEER program tested daily oral semaglutide (Rybelsus) in type 2 diabetes across placebo and active-comparator trials. Its cardiovascular safety study, PIONEER 6 (n=3,183), found a hazard ratio of 0.79 for major adverse cardiovascular events, meeting noninferiority versus placebo (NEJM 2019). Oral delivery of a peptide is itself notable — semaglutide was the first GLP-1 receptor agonist available as a tablet.

Two directions define current semaglutide research. In metabolic liver disease, a 72-week phase 2 trial in 320 patients with biopsy-confirmed NASH found resolution of steatohepatitis in 59% at the highest daily dose vs 17% on placebo — but no significant improvement in fibrosis stage, the harder endpoint (NEJM 2021).

In combinations, cagrilintide–semaglutide (CagriSema) pairs semaglutide with a long-acting amylin analog. The phase 3 REDEFINE 1 trial (n=3,417) reported −20.4% mean weight change vs −3.0% for placebo at 68 weeks (NEJM 2025) — territory previously reached only by tirzepatide and bariatric surgery.

Three habits keep semaglutide claims honest. Check the population — SELECT's 20% risk reduction was measured in people with existing cardiovascular disease, not healthy adults. Check the endpoint — NASH "resolution" and fibrosis improvement sound similar but only one was achieved. And check the product — every trial above used pharmaceutical-grade semaglutide with verified dosing, which is precisely what unregulated vials lack. For the head-to-head landscape, see semaglutide vs tirzepatide.